Apeloa Pharmaceutical Co.,Ltd
000739
주식 순위
#4291
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
주가
$3.13
시가총액
$3.62B
변동 (1일)
-1.42%
변동 (1년)
46.59%
국가
CN
거래 Apeloa Pharmaceutical Co.,Ltd (000739)
카테고리
Healthcare
Apeloa Pharmaceutical Co.,Ltd (000739)의 매출
Jun 2026 기준 매출 TTM: $1.37B
Apeloa Pharmaceutical Co.,Ltd의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.37B입니다. 2024년에 회사는 $1.65B의 수익을 올렸으며 이는 2023년의 $1.62B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Apeloa Pharmaceutical Co.,Ltd의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.37B | -1.63% |
| 2025 | $1.39B | -15.31% |
| 2024 | $1.65B | 1.61% |
| 2023 | $1.62B | 6.03% |
| 2022 | $1.53B | 8.65% |
| 2021 | $1.41B | 16.65% |
| 2020 | $1.21B | 16.48% |
| 2019 | $1.04B | 11.72% |
| 2018 | $926.93M | 8.63% |
| 2017 | $853.30M | 24.14% |
| 2016 | $687.35M | 2.89% |
| 2015 | $668.02M | -2.25% |
| 2014 | $683.37M | 7.52% |
| 2013 | $635.58M | 13.89% |
| 2012 | $558.08M | 25.04% |
| 2011 | $446.31M | 93.68% |
| 2010 | $230.44M | 15.01% |
| 2009 | $200.35M | 11.32% |
| 2008 | $179.98M | 26.18% |
| 2007 | $142.64M | -5.97% |
| 2006 | $151.70M | 18.26% |
| 2005 | $128.27M | 27.82% |
| 2004 | $100.36M | 7.83% |
| 2003 | $93.07M | 16.84% |
| 2002 | $79.66M | 364.75% |
| 2001 | $17.14M | -20.73% |
| 2000 | $21.62M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 381.89% |
IN
|
